Noribogaine
| Clinical data | |
|---|---|
| Other names | 12-Hydroxyibogamine; Ibogamin-12-ol; O-Desmethylibogaine; O-Demethylibogaine; O-Noribogaine; (–)-Noribogaine |
| Routes of administration | Oral |
| Drug class | κ-Opioid receptor agonist; serotonin reuptake inhibitor; oneirogen |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 24–50 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H24N2O |
| Molar mass | 296.414 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Noribogaine, also known as O-desmethylibogaine or 12-hydroxyibogamine, is the principal psychoactive metabolite of the oneirogen ibogaine. It may be involved in the potential antiaddictive effects of ibogaine and ibogaine-containing plant extracts, such as Tabernanthe iboga.
The drug appears to have a complex mechanism of action, with many different observed activities. Some of its most potent actions is atypical κ-opioid receptor agonism and serotonin reuptake inhibition. Noribogaine has potent psychoplastogenic effects similarly to ibogaine.
Noribogaine was first described in the scientific literature by 1958 and was first identified as a metabolite of ibogaine in 1995. It was first studied in humans in 2015.